Internal Medicine, Infectious Disease · Dacula, GA
NPI
1073718516
Since 2007
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3625 Braselton Hwy Ste 104
Dacula, GA, 30019
Phone (678) 206-2111
Groups this clinician bills Medicare through
Medicare paid, 2024
$604K
22,253 services
Medicare patients, 2024
438
Average age 74
Drug cost, 2024
$5.2M
2,024 prescriptions
Company payments, 2025
$206K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Andrew Dold was code J2406 (injection, oritavancin (kimyrsa), 10 mg), 6,480 times for 19 patients. In total Andrew Dold billed 22,253 services in 57 codes, and Medicare paid $604K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2406 Injection, oritavancin (kimyrsa), 10 mg | Office | 6,480 | 19 | $32.72 | $212K |
| J2407 Injection, oritavancin (orbactiv), 10 mg | Office | 3,240 | 13 | $21.87 | $71K |
| J0278 Injection, amikacin sulfate, 100 mg | Office | 534 | 22 | $0.62 | $331 |
| 96365 Intravenous Infusion, Hydration | Office | 255 | 50 | $48.25 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 240 | 122 | $12.48 | $2,996 |
| 96366 Intravenous Infusion, Hydration | Office | 240 | 23 | $15.37 | $3,688 |
| 99214 Office E&M - Established | Office | 231 | 110 | $92.35 | $21K |
| 99232 Hospital E&M - Subsequent | Facility | 152 | 105 | $59.99 | $9,119 |
| 99233 Hospital E&M - Subsequent | Facility | 119 | 98 | $89.72 | $11K |
| 99223 Hospital E&M - Initial | Facility | 90 | 88 | $130.69 | $12K |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 89 | 19 | $1.04 | $92.2 |
| 99213 Office E&M - Established | Office | 81 | 53 | $70.08 | $5,677 |
| J7060 5% dextrose/water (500 ml = 1 unit) | Office | 58 | 16 | $1.42 | $82.45 |
| 99222 Hospital E&M - Initial | Facility | 56 | 56 | $99.86 | $5,592 |
| 96372 Injection Administration | Office | 52 | 26 | $10.58 | $550 |
By year: 2022 $469K for 14,994 services; 2023 $463K for 13,611 services; 2024 $604K for 22,253 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 139 | 72 | $8.28 | $1,151 |
Medicare prescription drug claims, 2024
In 2024, the drug Andrew Dold prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 171 prescriptions and refills. In total Andrew Dold wrote 2,024 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 171 | 177 | 27 | $718K |
| Azithromycin Generic | 150 | 188 | 40 | $3,208 |
| Arikayce Amikacin Liposomal/Neb.Accessr | 106 | 108 | 22 | $1.6M |
| Nuzyra Omadacycline Tosylate | 104 | 104 | 52 | $912K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 87 | 181 | 38 | $982 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 83 | 83 | Under 11 | $242K |
| Doxycycline Hyclate Generic | 80 | 108 | 30 | $2,069 |
| Fluconazole Generic | 79 | 91 | 47 | $981 |
| Ethambutol Hcl Generic | 75 | 100 | 19 | $4,658 |
| Rifampin Generic | 66 | 80 | 12 | $2,189 |
| Cephalexin Generic | 63 | 133 | 27 | $4,609 |
| Methenamine Hippurate Generic | 61 | 108 | 22 | $3,084 |
| Ciprofloxacin Hcl Generic | 54 | 78 | 27 | $617 |
| Juluca Dolutegravir/Rilpivirine | 45 | 45 | Under 11 | $157K |
| Fosfomycin Tromethamine Generic | 43 | 72 | 21 | $18K |
Brand drugs: 838 claims; generic drugs: 1,186 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Andrew Dold $206K ($206K in general payments such as food, travel and fees) from 20 companies. The largest payer was Paratek Pharmaceuticals, Inc. with $173K.
| Company | Payments | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 272 | $173K |
| Gilead Sciences, Inc. GILD | 34 | $15K |
| ViiV Healthcare Company GSK | 21 | $7,708 |
| Cumberland Pharmaceuticals, Inc. CPIX | 11 | $6,474 |
| Pfizer Inc. PFE | 12 | $1,146 |
| Melinta Therapeutics, LLC | 32 | $1,100 |
| Ferring Pharmaceuticals Inc. | 4 | $717 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 8 | $218 |
| Insmed, Inc. INSM | 8 | $206 |
| Abbvie Inc. ABBV | 6 | $162 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.